A phase II study incorporating bone marrow microenvironment (ME) - co-targeting bortezomib into tandem melphalan-based autotransplants with DTPACE [cisplatin + doxorubicin + cyclophosphamide + etoposide] for induction/consolidation and thalidomide + dexamethasone for maintenance

Trial Profile

A phase II study incorporating bone marrow microenvironment (ME) - co-targeting bortezomib into tandem melphalan-based autotransplants with DTPACE [cisplatin + doxorubicin + cyclophosphamide + etoposide] for induction/consolidation and thalidomide + dexamethasone for maintenance

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Bortezomib (Primary) ; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Melphalan; Thalidomide
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms TT-IIIB
  • Most Recent Events

    • 05 Sep 2017 Planned End Date changed from 1 Aug 2017 to 1 Aug 2018.
    • 05 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.
    • 11 Oct 2016 Planned End Date changed from 1 Aug 2016 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top